Compendium of Cancer Genome Aberrations

Changes

HAEM5:Volunteer Assignments and Opportunities (view source)

Revision as of 13:14, 25 March 2024

138 bytes added ,  25 March
no edit summary
Line 2,141: Line 2,141:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), mentor needed
+
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee), Karin Miller, MD
−
| || || || ||SK|| ||
+
|3/25/2024
 +
| || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,182: Line 2,183:  
|Disease
 
|Disease
 
|Parastou Tizro (trainee) + Sumi Kitahara
 
|Parastou Tizro (trainee) + Sumi Kitahara
−
|3/17/24
+
|3/17/2024
 
|
 
|
 
|Pending
 
|Pending
Line 2,196: Line 2,197:  
|-
 
|-
 
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS
 
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Michelle Don, MD, MS
−
|3/17/24
+
|3/17/2024
 
|6/30/24
 
|6/30/24
 
|Pending
 
|Pending
Line 2,208: Line 2,209:  
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);  
 
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);  
 
Michelle Don, MD, MS
 
Michelle Don, MD, MS
−
|3/17/24
+
|3/17/2024
 
|6/30/24
 
|6/30/24
 
|Pending
 
|Pending
Line 2,226: Line 2,227:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||PENDING
+
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
−
| || || || ||SK|| ||
+
|3/22/2024
 +
| || || ||SK|| ||
 
|Sézary Syndrome
 
|Sézary Syndrome
 
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
 
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
Line 2,243: Line 2,245:  
|-
 
|-
 
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc
 
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Amanda Xu, MD/MSc
−
|3/19/24
+
|3/19/2024
 
| ||Pending
 
| ||Pending
 
| ||SK|| ||
 
| ||SK|| ||
Line 2,259: Line 2,261:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||PENDING
+
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
−
| || || || ||SK|| ||
+
|3/22/2024
 +
| || || ||SK|| ||
 
|Mycosis Fungoides
 
|Mycosis Fungoides
 
|Jane Scribner, MD and Daynna J. Wolff, PhD
 
|Jane Scribner, MD and Daynna J. Wolff, PhD
Line 2,283: Line 2,286:  
|-
 
|-
 
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
 
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Raniah Alamri (Hemepath trainee)
−
|3/19/24
+
|3/19/2024
 
| ||Pending
 
| ||Pending
 
| ||SK|| ||
 
| ||SK|| ||
Line 2,330: Line 2,333:  
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),  
 
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),  
 
Andrew Siref, MD
 
Andrew Siref, MD
−
|3/20/24
+
|3/20/2024
 
| ||Pending|| ||SK|| ||
 
| ||Pending|| ||SK|| ||
 
|Enteropathy-Associated T-cell Lymphoma
 
|Enteropathy-Associated T-cell Lymphoma
Line 2,340: Line 2,343:  
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),  
 
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee),  
 
Andrew Siref, MD
 
Andrew Siref, MD
−
|3/20/24
+
|3/20/2024
 
| ||Pending|| ||SK|| ||
 
| ||Pending|| ||SK|| ||
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
 
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
Line 2,358: Line 2,361:  
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);  
 
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);  
 
Michelle Don, MD, MS
 
Michelle Don, MD, MS
−
|3/19/24
+
|3/19/2024
 
|6/30/24
 
|6/30/24
 
|Pending
 
|Pending
Line 2,425: Line 2,428:  
|
 
|
 
|-
 
|-
−
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
 +
|6/25/2023
 +
| || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,432: Line 2,437:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/24|| ||Pending|| ||SK|| ||
+
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee), Andrew Siref, MD||3/22/2024|| ||Pending|| ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,440: Line 2,445:  
|-
 
|-
 
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc
 
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Amanda Xu, MD/MSc
−
|3/19/24
+
|3/19/2024
 
| ||Pending
 
| ||Pending
 
| ||SK|| ||
 
| ||SK|| ||
Line 2,463: Line 2,468:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease|| || || || || ||SK|| ||
+
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
 +
|3/25/2024
 +
| || || ||SK|| ||
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
 
|NEW (No Prior)
Line 2,470: Line 2,477:  
|NEW (No Prior)
 
|NEW (No Prior)
 
|-
 
|-
−
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||
+
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
−
| || || || ||SK|| ||prior authors not available
+
|3/25/2024
 +
| || || ||SK|| ||prior authors not available
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Systemic EBV-Positive T-cell Lymphoma of Childhood
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
 
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/14394...14396"